Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1992-5-18
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0145-2126
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
419-20
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1564945-Carboplatin,
pubmed-meshheading:1564945-Drug Synergism,
pubmed-meshheading:1564945-Humans,
pubmed-meshheading:1564945-Interferon-alpha,
pubmed-meshheading:1564945-Leukemia, Myeloid,
pubmed-meshheading:1564945-Neoplastic Stem Cells,
pubmed-meshheading:1564945-Tumor Stem Cell Assay
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Synergism between interferon-alpha and carboplatin in inhibiting K562 human myeloid leukaemia clonogenic cells: new potential therapeutic development.
|
| pubmed:publicationType |
Letter,
Research Support, Non-U.S. Gov't
|